Shareholder returns and the exploration-exploitation dilemma: R&D announcements by biotechnology firms

Research Policy

Volumn 36, Issue 4, 2007, Pages 548-565

  Mc Namara, Peter ^a   Baden Fuller, Charles ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b CITY UNIVERSITY   (United Kingdom)

Author keywords

Alliances; Event study; Financial performance; Knowledge based view; R D

Indexed keywords

BIOTECHNOLOGY; INNOVATION; KNOWLEDGE BASED SYSTEMS; PROJECT MANAGEMENT; RESEARCH AND DEVELOPMENT MANAGEMENT; TECHNOLOGY TRANSFER;

ALLIANCES; BIO-PHARMACEUTICAL FIRMS; EVENT STUDY; FINANCIAL PERFORMANCE;

SHAREHOLDERS;

EID: 34247646911     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2007.02.012     Document Type: Article

References (65)

1. Alchian A., and Demetz A. Production, information costs and economic performance. American Economic Review 62 (1972) 777-795
2. Alvarez S., and Barney J. How entrepreneurial firms can benefit from alliances with large partners. Academy of Management Executive 15 (2001) 139-148
3. Bayus B., Erickson G., and Jacobson R. The financial rewards of new product introductions in the personal computer industry. Management Science 49 (2003) 197-210
4. Biocentury, 2007. Biocentury Financial Center. Accessed 23 January. http://www.biocentury.com.
5. Bowerman B., and O'Connell R. Linear Statistical Models: An Applied Approach (1990), Belmont, Duxbury, CA
6. Brooks W. What will it take to get institutional investors interested in life sciences again?. Journal of Commercial Biotechnology 10 (2003) 22-28
7. Chan L., Lakonishok J., and Sougiannis T. The stock market valuation of research and development expenditures. The Journal of Finance LVI 6 (2001) 2431-2456
8. Chaney P., Devinney T., and Winer R. The impact of new product launches on the market value of firms. Journal of Business 64 (1991) 573-610
9. Chatterjee S., Lubatkin M., and Schulze W. Towards a strategic theory of risk premium: moving beyond CAPM. Academy of Management Review 24 (1998) 556-567
10. Chen S., Ho K., Ik K., and Lee C. How does strategic competition affect firm values? A study of new product announcements. Financial Management 31 (2002) 67-84
11. Cohen W., Goto A., Nagata A., Nelson R., and Walsh J. R&D spillovers, patents and the incentives to innovate in Japan and the United States. Research Policy 31 (2002) 1349-1367
12. Coriat B., and Orsi F. Establishing a new intellectual property rights regime in the United States origins, content and problems. Research Policy 31 (2002) 1491-1507
13. Daneels E. The dynamics of product innovation and firm competences. Strategic Management Journal 23 (2002) 1095-1121
14. Danzon P., Nicholson S., and Pereira N. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. Journal of Health Economics 25 (2005) 317-339
15. Das S., Sen P., and Sengupta S. Impact of strategic alliances on firm valuation. Academy of Management Journal 41 (1998) 27-41
16. DiMasi J., Hansen R., and Grabowski H. The price of innovation: New estimates of drug development costs. Journal of Health Economics 22 (2003) 151-185
17. DiMasi J., Grabowski H., and Vernon J. R&D costs, innovative outputs and firm size in the pharmaceutical industry. International Journal of the Economics of Business 2 (1995) 201-219
18. DiMasi J. Success rates for new Drugs entering clinical testing in the United States. Clinical Pharmacology and Therapeutics 58 (1995) 1-14
19. DiMasi J. New drug development in the United States from 1963 to 1999. Clinical Pharmacology and Therapeutics 69 (2001) 286-296
20. DiMasi J. The value of improving the productivity of the drug development process. Faster times and better decisions. Pharmacoeconomics 20 Supl 3 (2002) 1-10
21. Edelson S., and Brown S. Testing the limits. Biocentury July (2004) 1-9
22. Fama E. Efficient capital markets: II. The Journal of Finance 46 (1991) 1575-1614
23. Fama E., and French K. The cross-section of expected stock returns. The Journal of Finance XLVII (1992) 427-465
24. Flieger, K., 1995. Testing drugs in people. FDA Consumer Special Report on New Drug Development, http://www.fda.gov.
25. Gavetti G., and Levinthal D. Looking forward and looking backward: cognitive and experiential search. Administrative Science Quarterly 45 (2000) 113-137
26. Hoang H., and Rothaermel F. The effect of general and partner-specific alliance experience on joint R&D project performance. Academy of Management Journal 48 (2006) 332-345
27. Holmqvist M. Experiential learning processes of exploitation and exploration within and between organisations: an empirical study of product development. Organization Science 15 (2004) 70-81
28. Hyytinen A., and Toivanen O. Do financial constraints hold back innovation and growth? Evidence on the role of public policy. Research Policy 34 (2005) 1385-1403
29. Jagle A. Shareholder value, real options, and innovation in technology-intensive companies. R&D Management 29 (1999) 271-287
30. Jensen M., and Meckling W. Theory of the firm: Managerial behaviour, agency costs and ownership structure. Journal of Financial Economics 3 (1976) 305-360
31. Kale P., Dyer J., and Singh H. Alliance capability, stock market response, and long term alliance success: the role of the alliance function. Strategic Management Journal 23 (2002) 747-767
32. Kelm K., Narayanan V., and Pinches G. Shareholder value creation during R&D innovation and commercialization stages. Academy of Management Journal 38 (1995) 770-786
33. Khadaroo M., and Shaikh J. Toward research and development cost harmonization. The CPA Journal 73 9 (2003) 50-55
34. Lee J., Lee J., and Lee H. Exploration and exploitation in the presence of network externalities. Organization Science 49 (2003) 553-570
35. Levinthal D., and March J. The myopia of learning. Strategic Management Journal 14 (1993) 95-112
36. Littler C. A signalling theory of strategy. Academy of Management Conference, Best Paper Proceedings. Atlanta (2006)
37. MacKinlay A. Event studies in economics and finance. Journal of Economic Literature 35 (1997) 13-39
38. March J. Exploration and exploitation in organizational learning. Organization Science 2 (1991) 71-87
39. McConnell J., and Nantell T. Corporate combinations and common stock returns: the case of joint ventures. Journal of Finance 40 (1985) 519-536
40. McGrath R. Exploratory learning, innovative capacity, and managerial oversight. Academy of Management Journal 44 (2001) 118-131
41. McNamara P., Baden-Fuller C., and Howell J. The rejuvenation of Celltech in the 1990s: laying foundations of a FTSE 100 company. European Case Clearing House Collection (2000) (Code 300-072-1)
42. McWilliams A., and Siegel D. Event studies in management research: theoretical and empirical issues. Academy of Management Journal 40 (1997) 626-657
43. Menard, S., 1995. Applied logistic regression analysis. Sage University Paper Series On Quantitative Applications in the Social Sciences. Sage, Thousand Oaks, CA, pp. 07-106
44. Merchant H., and Schendel D. How do international joint ventures create shareholder value?. Strategic Management Journal 21 (2000) 723-737
45. Myers R. Classical and Modern Regression with Applications (1990), Duxbury, Boston, MA
46. Narayanan V., Pinches G., Kelm K., and Lander D. The influence of voluntarily disclosed qualitative information. Strategic Management Journal 21 (2000) 707-722
47. Niosi J. Alliances are not enough explaining rapid growth in biotechnology firms. Research Policy 32 (2003) 737-750
48. Park N. A guide to using event study methods in multi-country settings. Strategic Management Journal 25 (2004) 655-668
49. Pharmaceutical Research and Manufacturers of America, PhRMA, 2007. Inside R&D, http://www.innovation.org/index.cfm/nonav/inside_R_and_D, accessed 19 January 2007.
50. Powell W. Learning from collaboration: knowledge and networks in the biotechnology and pharmaceutical industries. California Management Review 40 3 (1998) 228-240
51. Robinson D., and Stuart T. Network effects in the governance of strategic alliances. Journal of Law, Economics and Organizations 23 1 (2007) 242-273
52. Robinson D., and Stuart T. Financial contracting in biotech strategic alliances. Journal of Law and Economics 50 3 (2007)
53. Roijakkers N., and Hagedoorn J. Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: trends, patterns, and networks. Research Policy 35 (2006) 431-446
54. Rothaermel F. Incumbents advantage through exploiting complimentary assets via interfirm cooperation. Strategic Management Journal 22 (2001) 687-699
55. Rothaermel F., and Deeds D. Exploration and exploitation alliances in biotechnology: a system of new product development. Strategic Management Journal 25 (2004) 201-221
56. Rothaermel F., and Deeds D. Alliance type, alliance experience, and alliance management capability in high technology ventures. Journal of Business Venturing 21 (2006) 429-460
57. Schulz M. The uncertain relevance of newness: organisational learning and knowledge flows. Academy of Management Journal 44 (2001) 661-681
58. Sorensen J., and Stuart T. Aging, obsolescence, and organizational innovation. Administrative Science Quarterly 45 (2000) 81-112
59. Teece D. Profiting from technological innovation: implications for integration, collaboration, licensing and public policy. Research Policy 15 (1986) 285-305
60. Torabzadeh K., Woodruff C., and Sen N. FDA decisions on New Drug Applications and the market value of pharmaceutical firms. American Business Review 16 2 (1998) 42-50
61. Tufts, 2005. New Drugs are taking Longer to bring to market in the U.S., according to Tufts Center for the Study of Drug Development. Accessed on 11 November 2005, http://csdd.tufts.edu/newsevents/newsarticle.asp?newsid=58.
62. Tylecote A., and Ramirez P. Corporate governance and innovation: the UK compared with the US and 'insider' economies. Research Policy 35 (2006) 160-180
63. Worrell D., Davidson W., Chang P., and Garrison S. Management turnover through death of key executives: Effects on investor wealth. Academy of Management Journal 29 (1986) 674-695
64. Xu B. Market differential evaluations of strategic alliances in the pharmaceutical/biotech industry. The Journal of High Technology Management Research 17 (2006) 43-52
65. Zhang J.C., Baden-Fuller C., and Mangematin V. Technological knowledge base. R&D organization structure and alliance formation: evidence from the biopharmaceutical Industry. Research Policy 36 (2007) 515-528